PALO ALTO, Calif.--Incyte Pharmaceuticals this month expanded a genomic partnership with Johnson & Johnson that began in 1996. Johnson & Johnson will receive access to multiple Incyte databses in exchange for annual fees, future milestone payments, and royalties to Incyte on the sale of products developed with its technology and data.
Among the databases is Incyte's newest product, the LifeSeq Gold assembled database, an extensive source of human gene and expression information assembled from preexisting Incyte databases using new and proprietary bioinformatics algorithms. Incyte claimed LifeSeq Gold is the most complete set of genetic data available on the human genome.
The deal also gives Johnson & Johnson access to Incyte's LifeSeq Atlas mapping and ZooSeq animal gene sequence and expression databases, as well as continued access to the PathoSeq microbial database.